-
Je něco špatně v tomto záznamu ?
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas
I. Zambo, M. Hermanova, D. Zapletalova, J. Skoda, P. Mudry, M. Kyr, K. Zitterbart, J. Sterba, R. Veselska,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
PubMed
27314299
DOI
10.3233/cbm-160623
Knihovny.cz E-zdroje
- MeSH
- ABC transportér z rodiny G, člen 2 genetika metabolismus MeSH
- antigen AC133 genetika metabolismus MeSH
- dítě MeSH
- dospělí MeSH
- exprese genu MeSH
- imunohistochemie MeSH
- Kaplanův-Meierův odhad MeSH
- kojenec MeSH
- lidé MeSH
- metastázy nádorů MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nádorové biomarkery * MeSH
- nádorové kmenové buňky metabolismus MeSH
- nestin genetika metabolismus MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- prognóza MeSH
- sarkom diagnóza genetika metabolismus mortalita MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Nestin, CD133 and ABCG2 are recently discussed as putative markers, co-expression of which might determine a cancer stem cell (CSC) phenotype in sarcomas. OBJECTIVE: Our study is focused on immunohistochemical analysis of nestin, CD133 and ABCG2 expression in rhabdomyosarcoma, Ewing sarcoma and osteosarcoma. Furthermore, we also analyzed the possible correlation of nestin, CD133 and ABCG2 expression levels with the patient outcome to identify potential prognostic values of these three putative CSC markers in the same cohorts. METHODS: Using immunohistochemistry, expression of nestin, CD133 and ABCG2 was analyzed in 24 rhabdomyosarcoma, 22 Ewing sarcoma and 10 osteosarcoma tissue samples and expression levels of these markers were correlated with clinical outcome. RESULTS: High nestin levels indicate poor prognosis in patients with Ewing sarcoma (P = 0.001), and high CD133 expression is associated with shorter survival in rhabdomyosarcoma patients (P = 0.002). In contrast, no significant relationship was found between ABCG2 expression and the clinical outcome. CONCLUSIONS: Our analysis represents the first complex study of these three putative CSCs markers together in three different types of pediatric sarcomas and showed their possible prognostic values in these tumors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013764
- 003
- CZ-PrNML
- 005
- 20170525144835.0
- 007
- ta
- 008
- 170413s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/CBM-160623 $2 doi
- 035 __
- $a (PubMed)27314299
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Zambo, Iva $u Department of Pathological Anatomy, Medical Faculty, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic. $7 xx0211296
- 245 10
- $a Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas / $c I. Zambo, M. Hermanova, D. Zapletalova, J. Skoda, P. Mudry, M. Kyr, K. Zitterbart, J. Sterba, R. Veselska,
- 520 9_
- $a BACKGROUND: Nestin, CD133 and ABCG2 are recently discussed as putative markers, co-expression of which might determine a cancer stem cell (CSC) phenotype in sarcomas. OBJECTIVE: Our study is focused on immunohistochemical analysis of nestin, CD133 and ABCG2 expression in rhabdomyosarcoma, Ewing sarcoma and osteosarcoma. Furthermore, we also analyzed the possible correlation of nestin, CD133 and ABCG2 expression levels with the patient outcome to identify potential prognostic values of these three putative CSC markers in the same cohorts. METHODS: Using immunohistochemistry, expression of nestin, CD133 and ABCG2 was analyzed in 24 rhabdomyosarcoma, 22 Ewing sarcoma and 10 osteosarcoma tissue samples and expression levels of these markers were correlated with clinical outcome. RESULTS: High nestin levels indicate poor prognosis in patients with Ewing sarcoma (P = 0.001), and high CD133 expression is associated with shorter survival in rhabdomyosarcoma patients (P = 0.002). In contrast, no significant relationship was found between ABCG2 expression and the clinical outcome. CONCLUSIONS: Our analysis represents the first complex study of these three putative CSCs markers together in three different types of pediatric sarcomas and showed their possible prognostic values in these tumors.
- 650 _2
- $a antigen AC133 $x genetika $x metabolismus $7 D000071916
- 650 _2
- $a ABC transportér z rodiny G, člen 2 $x genetika $x metabolismus $7 D000070997
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a exprese genu $7 D015870
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a nádorové kmenové buňky $x metabolismus $7 D014411
- 650 _2
- $a nestin $x genetika $x metabolismus $7 D064231
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a sarkom $x diagnóza $x genetika $x metabolismus $x mortalita $7 D012509
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hermanova, Marketa $u Department of Pathological Anatomy, Medical Faculty, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.
- 700 1_
- $a Zapletalova, Danica $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Skoda, Jan $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic. Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Mudry, Peter $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Kyr, Michal $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Zitterbart, Karel $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Sterba, Jaroslav $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Veselska, Renata $u Department of Pediatric Oncology, Medical Faculty, Masaryk University and University Hospital Brno, Brno, Czech Republic. Laboratory of Tumor Biology, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic.
- 773 0_
- $w MED00173146 $t Cancer biomarkers section A of Disease markers $x 1875-8592 $g Roč. 17, č. 1 (2016), s. 107-16
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27314299 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170525145234 $b ABA008
- 999 __
- $a ok $b bmc $g 1200229 $s 974542
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 17 $c 1 $d 107-16 $i 1875-8592 $m Disease markers. Section A, Cancer Biomarkers $n Cancer Biomark $x MED00173146
- LZP __
- $a Pubmed-20170413
